As of 6 Nov 2026, Procter & Gamble Health trades at 26.5× trailing earnings, below the industry P/E of 28.7×, and the shares are 20% below their 52-week high. Its ROCE of 77% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 2.7%. It is a small-cap company with a market cap of ₹9,223 Cr, ranked 34th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 7.6% over the past year.
- ₹5,600.00
- ₹5,600.00
- ₹5,485.00
- ₹5,605.00
- 7K
Health check
- ReturnsBehind
−7.6% over a year, better than 0 of 7 peers.
- Price tagIn line
P/E 26.5 vs industry 28.7.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityStrong
ROCE 76.8% vs peer median 17.9%.
- Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹9,223 Cr
- Small cap
- P/E
- 26.5
- Industry 28.7
- Price to book
- 17.58
- Peers 4.99
- Dividend yield
- 2.66%
- ROE
- 61.5%
- Peers 14.7%
- ROCE
- 76.8%
- Peers 17.9%
- Debt to equity
- 0.02
- Debt ₹9.29 Cr
- EPS (TTM)
- ₹209.67
- Face value ₹10
- OPM (TTM)
- 33.4%
- Net margin 24.9%
- Sales growth
- +17.7%
- Latest quarter vs a year ago
- Profit growth
- +25.9%
- Latest quarter vs a year ago
- Price to sales
- 6.44
- EV/EBITDA 30.8
Strengths and risks
Strengths
- Return on equity of 61.5%.
- Return on capital employed of 76.8%.
- Practically debt-free.
- Dividend yield of 2.66%.
- Quarterly profit up 25.9% on a year ago.
About Procter & Gamble Health
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was…
- Headquarters
- Mumbai
- Employees
- 1,276
- Sector
- Healthcare
- ISIN
- INE199A01012
- Website
- pghealthindia.com
Price range
- Avg volume (3M)
- 13K
- 1-year return
- minus 7.6%
- From 52-week high
- minus 20.3%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.87% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.30% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.81% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.59% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.93% | minus 6.6% |
| PGHLProcter & Gamble Health | 5,556.00 | minus 0.87% | 9,223 | 26.5 | 17.58 | 76.8% | 61.5% | 33.4% | – | – | 2.66% | minus 7.6% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.59% | 22.8% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 325 | 374 | 370 | 364 | 382 | |
| 205 | 263 | 235 | 264 | 230 | |
| 120 | 110 | 136 | 99.6 | 152 | |
| 37.0% | 29.5% | 36.6% | 27.4% | 39.8% | |
| 5 | 4.4 | 4 | 3.9 | 3.9 | |
| 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | |
| 6.1 | 5.9 | 6.2 | 6 | 6.1 | |
| – | – | – | 31.8 | – | |
| 119 | 109 | 133 | 129 | 150 | |
| 25.6% | 28.7% | 29.0% | 25.5% | 25.7% | |
| 88.5 | 77.6 | 94.6 | 96.2 | 112 | |
| 53.54 | 46.74 | 56.99 | 57.92 | 67.18 |
Profit & loss
- ROE
- 61.5%
| ₹ Cr | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|
| 1,092 | 1,206 | 1,129 | 1,385 | |
| – | +10.4% | minus 6.3% | – | |
| 817 | 882 | 823 | 927 | |
| 275 | 324 | 307 | 459 | |
| 25.2% | 26.9% | 27.1% | 33.1% | |
| 12.5 | 17.7 | 15.6 | 17.3 | |
| 0.4 | 0.8 | 0.7 | 0.6 | |
| 27.1 | 28.1 | 27.4 | 23.6 | |
| −6.5 | 1.4 | −20.7 | −1.9 | |
| 253 | 314 | 273 | 450 | |
| 24.0% | 27.0% | 26.5% | 27.3% | |
| 193 | 229 | 201 | 327 | |
| – | +19.2% | minus 12.4% | – | |
| 116.00 | 138.00 | 121.00 | 197.00 |
Forecast
Balance sheet
| ₹ Cr | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|
| 16.6 | 16.6 | 16.6 | 16.6 | |
| 600 | 734 | 522 | 508 | |
| 2.8 | 12 | 9.6 | 9.3 | |
| 269 | 338 | 247 | 308 | |
| 888 | 1,101 | 794 | 841 | |
| 150 | 173 | 132 | 113 | |
| 40.6 | 32.7 | 5.9 | 13.6 | |
| 8.8 | 5.1 | 6.2 | 4.8 | |
| 319 | 435 | 239 | 177 | |
| 370 | 455 | 412 | 533 | |
| 888 | 1,101 | 794 | 841 |
Cash flow
| ₹ Cr | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 |
|---|---|---|---|---|
| 170 | 236 | 228 | 338 | |
| −25.5 | −21.5 | −6.9 | 1.3 | |
| −289 | −98.5 | −418 | −344 | |
| −145 | 116 | −197 | −4.9 | |
| −37.9 | −42.5 | −21.7 | −15.5 | |
| 132 | 194 | 207 | 322 | |
| −284 | −93.8 | −415 | −340 |
Shareholding pattern
- Promoters51.82%
- Public48.18%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 51.82% | 48.18% | 0.00 | |
| 30 Jun 2026 | 51.82% | 48.18% | 0.00 | |
| 31 Mar 2026 | 51.82% | 48.18% | 0.00 | |
| 31 Dec 2025 | 51.82% | 48.18% | 0.00 | |
| 30 Sep 2025 | 51.82% | 48.18% | – |
Major shareholders
Filings & events
News
No recent news coverage found.